Etrumadenant + IPI-549 + Pegylated liposomal doxorubicin (PLD) + nanoparticle albumin-bound paclitaxel (NP)

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

TNBC - Triple-Negative Breast Cancer

Conditions

TNBC - Triple-Negative Breast Cancer, Ovarian Cancer

Trial Timeline

Oct 15, 2018 → Jul 2, 2021

NCT ID

NCT03719326

About Etrumadenant + IPI-549 + Pegylated liposomal doxorubicin (PLD) + nanoparticle albumin-bound paclitaxel (NP)

Etrumadenant + IPI-549 + Pegylated liposomal doxorubicin (PLD) + nanoparticle albumin-bound paclitaxel (NP) is a phase 1 stage product being developed by Arcus Biosciences for TNBC - Triple-Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03719326. Target conditions include TNBC - Triple-Negative Breast Cancer, Ovarian Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03719326	Phase 1	Completed	Oct 15, 2018	Jul 2, 2021	TNBC - Triple-Negative Breast Cancer

Competing Products

14 competing products in TNBC - Triple-Negative Breast Cancer

See all competitors

Product	Company	Stage	Hype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825	Boundless Bio	Phase 1	25
Fluzoparib+Paclitaxel + Epirubicin+Cyclophosphamide	Jiangsu Hengrui Medicine	Phase 2	52
olaparib + Durvalumab	AstraZeneca	Phase 2	52
AZD 1775	AstraZeneca	Phase 1	33
Pembrolizumab + Axatilimab	Merck	Phase 2	52
Pembrolizumab + Axatilimab	Merck	Phase 2	52
Pembrolizumab + Nab-paclitaxel + Paclitaxel + Gemcitabine + Carboplatin + Normale Saline Solution	Merck	Phase 3	77
spartalizumab + LAG525 + NIR178 + capmatinib + MCS110 + canakinumab	Novartis	Phase 1	33
MCS110 + carboplatin + gemcitabine	Novartis	Phase 2	52
Gedatolisib + Talazoparib	Pfizer	Phase 1/2	40
AK112 + Nab-paclitaxel + Placebo	Akeso	Phase 3	76
IVAC_W_bre1_uID + IVAC_W_bre1_uID/IVAC_M_uID	BioNTech	Phase 1	30
Ivonescimab + Carboplatin + Docetaxel	Summit Therapeutics	Phase 2	49
Leucovorin + 5-Fluorouracil + Aldoxorubicin HCl + nab-Paclitaxel + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6207 + GI-6301 + Avelumab + ALT-803 + haNK + Cyclophosphamide + Doxorubicin HCL + paclitaxel	ImmunityBio	Phase 2	49

Other Products from Arcus Biosciences

Casdatifan + Cabozantinib + PlaceboPhase 3

Quemliclustat + Placebo + Nab-paclitaxel + GemcitabinePhase 3

Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Phase 2

Etrumadenant (AB928) + FOLFOX regimen + Zimberelimab (AB122)Phase 2

Zimberelimab + DomvanalimabPhase 2